Clinical trials: Diabetes Mellitus Type II,
Insulin Resistance - Type A, Insulin Resistance - Type B
A Study of Empagliflozin in Patients With Refractory Diabetes Mellitus With Insulin Resistance
A multicenter, open-label, single-arm study with regard to the efficacy and safety of empagliflozin in patients with refractory diabetes mellitus with insulin resistance
- Conditions
- Insulin Resistance - Type A, Insulin Resistance - Type B, Lipoatrophic Diabetes Mellitus, Insulin Resistance Syndrome
- Trial name
- EMPIRE-01 (NCT04018365)
- Testing
- Empagliflozin Tablets
- Where
- 5 sites in Japan
- Volunteers
- 8 people
- Sponsor
- Kobe University
Type 2 Diabetes Mellitus, Type 2 Diabetes
Long-term Study to Evaluate the Safety of Dutogliptin/PHX1149T in Subjects With Type 2 Diabetes Mellitus
The purpose of this study is to demonstrate that dutogliptin/PHX1149T is safe and tolerable.
- Trial name
- NCT00865592
- Testing
- dutogliptin
- Where
- 68 sites in United States, Argentina and 6 more
- Volunteers
- 450 people
- Sponsor
- Phenomix
Diabetes Mellitus, Type II
A Clinical Study to Compare the Pharmacokinetic Characteristics of CKD-395 0.25/500mg in Healthy Male Volunteers
This study is a randomized, open-label, single dose, 2-way crossover study to compare the pharmacokinetic characteristics of CKD-395 0.25/500 mg in healthy male volunteers.
- Trial name
- NCT02685774
- Testing
- Duvie Tab. 0.5mg, Glucophage XR Tab. 500mg, CKD-395 0.25/500mg
- Where
- South Korea
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Type 2 Diabetes Mellitus
Comparison of SAR342434 to Humalog as the Rapid Acting Insulin in Adult Patients With Type 2 Diabetes Mellitus Also Using Insulin Glargine
Primary Objective: To demonstrate non-inferiority of SAR342434 versus Humalog in glycated hemoglobin A1c (HbA1c) change from baseline to Week 26 in participants with type 2 diabetes mellitus (T2DM) also using insulin glargine.
- Trial name
- SORELLA2 (NCT02294474)
- Testing
- SAR342434, Humalog, insulin glargine HOE901
- Where
- 103 sites in United States, Argentina and 10 more
- Volunteers
- 505 people
- Sponsor
- Sanofi
Diabetes
Effect of Nutritional Products in Subjects With Type 2 Diabetes
This is a randomized, double blinded, multi treatment, crossover study intended to compare the glycemic and insulinemic response after consuming liquid nutritional products in people with type 2 diabetes.
- Trial name
- NCT02923960
- Testing
- Standard ONS, Diabetes specific ONS 1, Diabetes specific ONS 2
- Where
- 2 sites in United States
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- Abbott Nutrition
Chronic Kidney Disease, Type 2 Diabetes Mellitus
An Observational Study Called FIRST-2.0 to Learn More About the Use of the Study Treatment Finerenone Including How Safe it is and How Well it Works Under Real-world Conditions
This is an observational study, in which data from people in the United States (US) with chronic kidney disease (CKD) together with type 2 diabetes (T2D) are studied.
- Trial name
- FIRST-2 (NCT05703880)
- Testing
- Finerenone (Kerendia, BAY948862)
- Where
- 2 sites in United States
- Volunteers
- 15,948 people
- Sponsor
- Bayer
Type 2 Diabetes
A Phase 3 Study to Evaluate Efficacy and Safety of HDM1002 Tablets in Adults With Type 2 Diabetes Mellitus
This is a multicenter, randomized, double-blind, active-controlled, parallel-group study, which aims to provide data on the efficacy and safety of HDM1002 tablets compared with dapagliflozin in adults with type 2 diabetes…
- Trial name
- NCT07082114
- Testing
- HDM1002 100 mg, HDM1002 200 mg, HDM1002 400 mg
- Where
- China
- Volunteers
- 800 people
- Sponsor
- Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Type 2 Diabetes Mellitus
The Efficacy and Safety of Different Doses of SY-004 in Patients With Type 2 Diabetes Mellitus
This is a multicenter, randomized, double-blind, placebo-controlled phase II clinical study in patients with type 2 diabetes mellitus (T2DM).
- Trial name
- NCT04217291
- Testing
- SY-004
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Suzhou Yabao Pharmaceutical R&D Co., Ltd.
Diabetic Foot Ulcer, Diabetic Foot
Modified Platform Trial Evaluating PpLHACM and SOC Versus SOC Alone in the Treatment of Nonhealing DFUs
This study will evaluate two human amnion/chorion membrane (ppLHACM) products and Standard of Care (SOC) versus SOC alone in the closure of nonhealing diabetic foot ulcers (DFUs).
- Conditions
- Diabetic Foot Ulcer, Diabetic Foot, Foot Ulcer Due to Type 2 Diabetes Mellitus, Foot Ulcer, Diabetic
- Trial name
- CAMPAIGN (NCT06600724)
- Testing
- Standard of Care, EPIEFFECT, EPIXPRESS
- Where
- United States
- Volunteers
- 170 people
- Sponsor
- MiMedx Group, Inc.
Diabetes, Diabetes Mellitus, Type 1
Observational Study of Patients Using NovoMix® 30 or Levemir® for Treatment of Type 1 or Type 2 Diabetes
This trial is conducted in Europe. The aim of this observational study is to evaluate the glycaemic control in patients with type 1 or 2 diabetes using NovoMix® 30 or Levemir® under normal clinical practice conditions.
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Trial name
- NCT00671008
- Testing
- biphasic insulin aspart 30, insulin detemir
- Where
- Bosnia and Herzegovina
- Volunteers
- 400 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes Mellitus
Bioequivalence Study of 2.5-mg Saxagliptin and 500-mg Glucophage in Tablets and a Fixed-dose Combination Tablet in Healthy Participants
To demonstrate the bioequivalence of a 2.5-mg saxagliptin/500-mg metformin fixed-dose combination (FDC) tablet to that of 2.5-mg saxagliptin (Onglyza) and 500-mg metformin (Glucophage, marketed in Canada by Sanofi-Aventis)…
- Trial name
- NCT01068717
- Testing
- Saxagliptin, 2.5 mg + Metformin, 500 mg (fasted state), Saxagliptin, 2.5 mg /Metformin, 500 mg FDC (fasted state), Saxagliptin, 2.5 mg + Metformin, 500 mg (fed state)
- Where
- United States
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Type 2 Diabetes Mellitus
Multiple Ascending Dose Study in Healthy Male Subjects and Overweight to Obese Male and Female Type 2 Diabetes Mellitus (T2DM) Patients
Primary Objective: To assess in healthy adult male subjects: The tolerability and safety of 21-day repeated subcutaneous (SC) doses of SAR425899 including two up titration steps.
- Trial name
- NCT02411825
- Testing
- SAR425899, metformin
- Where
- Germany
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- Sanofi
Healthy Volunteers, Diabetes Mellitus, Type 2
A Research Study of How Oral Semaglutide Tablets Work in Healthy People Who Are Chinese
This study looks at the way a new medicine tablet called semaglutide moves in and throughout the body over time. It will also look at if the medicine is safe and the body can accept it.
- Trial name
- NCT04016974
- Testing
- Oral semaglutide
- Where
- China
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 2
A Trial to Investigate the Single Dose Pharmacokinetics of Insulin Degludec/Liraglutide Compared With Insulin Degludec and Liraglutide in Healthy Chinese Subjects
The main purpose of the trial is to compare the bioavailability (extent of drug absorption into the circulation) of insulin degludec and liraglutide as part of a combination product insulin degludec/liraglutide compared to the…
- Trial name
- NCT03292185
- Testing
- insulin degludec/liraglutide, insulin degludec, liraglutide
- Where
- China
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Obesity, Overweight
A Study of LY3549492 in Adults With Obesity or Overweight With Type 2 Diabetes
The main purpose of this study, performed under the master protocol W8M-MC-CWMM (NCT06143956), is to evaluate the effects of treatment with LY3549492 compared to placebo in adult participants with obesity or who are overweight…
- Conditions
- Obesity, Overweight, Type 2 Diabetes
- Trial name
- NCT07030868
- Testing
- LY3549492
- Where
- 42 sites in United States, Argentina
- Volunteers
- 1 people
- Sponsor
- Eli Lilly and Company
Type 2 Diabetes
A Study of OPC-262 in Patients With Type 2 Diabetes
The purpose of this clinical study is to evaluate the safety and efficacy of OPC-262 5 mg in patients with type 2 diabetes by repeated administration orally for 52 weeks.
- Trial name
- NCT01046318
- Testing
- OPC-262
- Where
- 3 sites in Japan
- Volunteers
- 100 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Diabetes, Diabetes Mellitus, Type 2
Comparing the Efficacy and Safety of NN1250 Once Daily When Titrated Using 2 Different Algorithms in Insulin naïve Subjects With Type 2 Diabetes Mellitus
This trial is conducted in Europe and the United States of America (USA). The aim of this trial is to compare the efficacy and safety of NN1250 (insulin degludec (IDeg)) once daily in insulin naïve subjects with type 2 diabetes…
- Trial name
- BEGIN™ (NCT01326026)
- Testing
- insulin degludec
- Where
- 45 sites in United States, Finland and 2 more
- Volunteers
- 222 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes Mellitus
Proteus Sustained Behavior Change Study
The study will test whether the Proteus Sustained Behavior Change (SBC) System will help Type 2 diabetics feel more able to perform self-care activities, feel less distressed about diabetes, and reduce mean fasting blood glucose…
- Trial name
- NCT01503008
- Testing
- Proteus Sustained Behavior Change system, Regularly prescribed diabetes medicines (metformin, sulfonylureas, thiazolidinediones, DPP-IV inhibitors, alpha-glucosidase inhibitors)
- Where
- 2 sites in United States
- Sponsor
- Proteus Digital Health, Inc.
Type 2 Diabetes Mellitus
Observational Study of Triple Combination Therapy of Zemidapa Tab. and Metformin in Type 2 Diabetes Mellitus Patients
The aim of this study is to evaluate the effectiveness and safety of the triple combination therapy of Zemidapa Tab. and Metformin in patients with type 2 diabete mellitus
- Trial name
- NCT06495281
- Where
- South Korea
- Volunteers
- 2,044 people
- Sponsor
- LG Chem
Diabetes Mellitus, Type 2
Effect on Glycemic Control of Inhaled Insulin Alone or Added to Dual Oral Therapy After Failure of Dual Oral Therapy.
To assess the impact on glucose control by inhaled insulin alone or added to two oral anti-diabetic agents in patients with type 2 diabetes who are not well controlled on 2 oral anti-diabetic agents.
- Trial name
- NCT00370565
- Testing
- Inhaled Human Insulin
- Where
- 52 sites in United States, Canada
- Volunteers
- 345 people
- Sponsor
- Pfizer
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.